MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

Leukemia

Volumn 18, Issue 8, 2004, Pages 1380-1390

  Feller, N ^a   van der Pol, M A ^a   van Stijn, A ^a   Weijers, G W D ^a   Westra, A H ^a   Evertse, B W ^a   Ossenkoppele, G J ^a   Schuurhuis, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AML; Immunophenotype; Minimal residual disease; PBSC products

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; LEUKEMIA ANTIGEN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOLOGICAL PARAMETERS; IMMUNOPHENOTYPING; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MINIMAL RESIDUAL DISEASE; OUTCOMES RESEARCH; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECURRENCE RISK; RELIABILITY; RISK ASSESSMENT;

EID: 4344688843     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403405     Document Type: Article

References (24)

1. Macedo A, Orfao A, Vidriales MB, Lopez-Berges MC, Valverde B, Gonzalez M et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995; 70: 189-194.
2. Macedo A, Orfao A, Gonzalez M, Vidriales MB, Lopez-Berges MC, Martinez A et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995; 9: 993-998.
3. Reading CL, Estey EH, Hub YO, Claxton DF, Sanchez G, Terstappen LW et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
4. van der Pol MA, Pater JM, Feller N, Westra AH, van Stijn A, Ossenkoppele GJ et al. Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia 2001; 15: 1554-1563.
5. Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb HJ et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003; 88: 646-653.
6. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470.
7. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152.
8. van Dongen JJ, Szczepanski T, de Bruijn MA, van den Beemd MW, de Bruin-Versteeg S, Wijkhuijs JM et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996; 2: 121-133.
9. Yin JA, Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002; 360: 160-162.
10. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746-1751.
11. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948-3952.
12. Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003; 101: 3398-3406.
13. San Miguel JF, Vidriales MB, Orfao A. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML). Best Pract Res Clin Haematol 2002; 15: 105-118.
14. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-1958.
15. Vellenga E, van Putten WL, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant 1999; 23: 1279-1282.
16. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
17. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD et al. Report of the National Cancer Institute - sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
18. Macedo A, San Miguel JF, Vidriales MB, Lopez-Berges MC, Garcia-Marcos MA, Gonzalez M et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol 1996; 49: 15-18.
19. Baer MR, Stewart CC, Dodge RK, Leget G, Sule N, Mrozek K et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97: 3574-3580.
20. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38: 1677-1684.
21. Reichle A, Rothe G, Krause S, Zaiss M, Ullrich H, Schmitz G et al. Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Leukemia 1999; 13: 1227-1234.
22. Feller N, Schuurhuis GJ, van der Pol MA, Westra G, Weijers GW, van Stijn A et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003; 17: 68-75.
23. Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 1993; 328: 614-619.
24. Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003; 17: 2178-2182.